The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
Open accessAbstract
Background.: Borderline resectable pancreatic cancer is best treated by multimodality therapy. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) tripled the response rate and significantly increased median survival for patients with advanced pancreatic cancer and shows promise for neoadjuvant use. Toxicity concerns prompted a careful analysis of our initial FOLFIRINOX experience. Methods.: All patients diagnosed with borderline resectable, biopsy-proven pancreatic adenocarcinoma treated with neoadjuvant FOLFIRINOX between July 2010 and December 2012 were reviewed. Primary outcome was surgical resectability. Secondary outcomes were treatment-related toxicities and survival. Results.: FOLFIRINOX followed by gemcitabine- or capecitabine-based chemoradiation was initiated in 18 patients. The most common grade 3 or 4 toxicities during chemotherapy were gastrointestinal, including nausea/emesis (n = 5), weight loss (n = 3) and diarrhea (n = 2), and hematologic (n = 2; neutropenia); five patients (36%) required a total of six admissions. Neoadjuvant therapy was completed in 15 of 18 patients (83%), and 12 (67%) underwent pancreatectomy (10 Whipple, 2 total pancreatectomy) including portal vein resection/reconstruction in 10 (83%). Disease progression precluded surgery in 6 of the 18 patients (33%). All 12 resected patients had negative (R0) margins. Only 2 of 12 (17%) were node positive (median node count: 26.5 [range: 15–39]). There were no in-hospital or 30-day mortalities and no clinical pancreatic leaks or reoperations. Of the 12 patients who completed all intended therapy, 7 (58.3%) are alive, including 5 who have no evidence of disease (median months from diagnosis: 22 months [range: 18–35 months). The six patients who did not complete all planned therapy are deceased (months from diagnosis: 6.9–17.5 months). Conclusion.: FOLFIRINOX followed by chemoradiation as neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma is safe, and our initial experience suggests favorable resection rates compared with previous reports in this high-risk patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Cited by
Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000867 · Cited by 842
Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., Strobel, O., Jäger, D., Ulrich, A., & Büchler, M. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001850 · Cited by 529
Katz, M. H. G., Shi, Q., Ahmad, S. A., Herman, J. M., Marsh, R. D. W., Collisson, E., Schwartz, L., Frankel, W., Martin, R., Conway, W., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.1137 · Cited by 448
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
Joglekar, S., Asghar, A., Mott, S. L., Johnson, B. E., Button, A. M., Clark, E., & Mezhir, J. J. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23862 · Cited by 275
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Alhusaini, A., Cannon, A., Maher, S. G., Reynolds, J. V., & Lynam-Lennon, N. (2021) · Biomedicines · doi:10.3390/biomedicines9081024 · Cited by 24
Metadata
- Authors
- Christians, K. K., Tsai, S., Mahmoud, A., Ritch, P., Thomas, J. P., Wiebe, L., Kelly, T., Erickson, B., Wang, H., Evans, D. B., & George, B.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-25
- Volume
- 19
- Issue
- 3
- Pages
- 266-274
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2146997862
- Cited by
- 190
- References
- 1
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? https://app.cochat.ai/papers/10.1634/theoncologist.2013-0273
- The paper
- Christians, K. K., Tsai, S., Mahmoud, A., Ritch, P., Thomas, J. P., Wiebe, L., Kelly, T., Erickson, B., Wang, H., Evans, D. B., & George, B. (2014). Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? The Oncologist. https://doi.org/10.1634/theoncologist.2013-0273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.